Welcome to EBE, the Voice of Biopharmaceuticals in Europe

All stakeholders should stand to benefit from the advances in healthcare that biopharmaceutical technology offers and they all have a role to play. EBE has become a key focal point for information exchange between the research-based biopharmaceutical industry operating in Europe and all major stakeholders engaged in this process.

Biotechnology is delivering significant advances in human healthcare. Entirely new medicines are being created, notably for rare or previously untreated diseases. Biotech production methods provide safer versions of existing treatments in unlimited quantities. Biotechnology has revolutionised the research and development of new medicines and allows better product targeting for specific diseases and patient groups. A greater understanding of the genetic causes of disease allows early detection and treatment, and the new field of gene therapy may even herald the possibility to cure diseases, not simply treat them.

Current Issues
Industry Recommendations on Clinical Added Value of Orphan Drugs Position Paper of the Joint EBE-EuropaBio Task Force on Rare Diseases and Orphan Medicinal Products (25 November 2009) more	IMI – 2nd Call for Research Proposals Published – 8 Feb. 2010 as Deadline The Innovative Medicines Initiative (IMI) has officially launched a second call for proposals with a total funding of €156.3 million out of which, €76.8 million will be provided by the European Commission and €79.5 million expected to be provided in kind from EFPIA member companies. more
European Commission and biopharma sector lay out steps to improve business environment Brussels, December 1st, 2009: EBE, the European Biopharmaceutical Enterprises and the European Commission’s Enterprise and Industry Directorate General today jointly presented a workshop on access to finance for small and medium-sized biopharmaceutical companies in Europe. The workshop is a major step forward in finding new solutions to support and underpin at-risk European biopharmaceutical SMEs, which have been hit hard by the economic challenges of the global financial crisis. The workshop marked the release of a Commission-funded study on the financing of biopharmaceutical product development in Europe. The study highlights the decreasing levels of venture capital available for biopharmaceutical SMEs, as well as the impact of the global economic crisis on access to liquidities and credit. more	Key stakeholders should share responsibility of balancing the benefits and risks from new medicines Bad Hofgastein, 1 October 2009: The European Biopharmaceutical Enterprises (EBE) hosted a lunch workshop co-sponsored by EBE, Novartis and Roche during the European Health Forum Gastein on “Biopharmaceuticals: Balancing Benefits and Risks - Sharing Responsibility”. The event highlighted the need to share responsibility amongst key stakeholders during the development process of a medicinal product, from its research and conception until its release on the market. Sharing responsibility would help ensure a balanced approach that reflects the interests of all parties concerned. more

Current Issues

Industry Recommendations on Clinical Added Value of Orphan Drugs

Position Paper of the Joint EBE-EuropaBio Task Force on Rare Diseases and Orphan Medicinal Products (25 November 2009)

IMI – 2nd Call for Research Proposals Published – 8 Feb. 2010 as Deadline

The Innovative Medicines Initiative (IMI) has officially launched a second call for proposals with a total funding of €156.3 million out of which, €76.8 million will be provided by the European Commission and €79.5 million expected to be provided in kind from EFPIA member companies.

European Commission and biopharma sector lay out steps to improve business environment

Brussels, December 1st, 2009: EBE, the European Biopharmaceutical Enterprises and the European Commission’s Enterprise and Industry Directorate General today jointly presented a workshop on access to finance for small and medium-sized biopharmaceutical companies in Europe. The workshop is a major step forward in finding new solutions to support and underpin at-risk European biopharmaceutical SMEs, which have been hit hard by the economic challenges of the global financial crisis. The workshop marked the release of a Commission-funded study on the financing of biopharmaceutical product development in Europe. The study highlights the decreasing levels of venture capital available for biopharmaceutical SMEs, as well as the impact of the global economic crisis on access to liquidities and credit.

Key stakeholders should share responsibility of balancing the benefits and risks from new medicines

Bad Hofgastein, 1 October 2009: The European Biopharmaceutical Enterprises (EBE) hosted a lunch workshop co-sponsored by EBE, Novartis and Roche during the European Health Forum Gastein on “Biopharmaceuticals: Balancing Benefits and Risks - Sharing Responsibility”. The event highlighted the need to share responsibility amongst key stakeholders during the development process of a medicinal product, from its research and conception until its release on the market. Sharing responsibility would help ensure a balanced approach that reflects the interests of all parties concerned.

european biopharmaceutical enterprises

Welcome to EBE, the Voice of Biopharmaceuticals in Europe

Industry Recommendations on Clinical Added Value of Orphan Drugs

IMI – 2nd Call for Research Proposals Published – 8 Feb. 2010 as Deadline

European Commission and biopharma sector lay out steps to improve business environment

Key stakeholders should share responsibility of balancing the benefits and risks from new medicines

Members Login